Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
KYMR Stock Chart & Stats
$83.49
-$0.34(-0.84%)
At close: 4:00 PM EST
$83.49
-$0.34(-0.84%)
Day’s Range― - ―
52-Week Range$19.45 - $103.00
Previous CloseN/A
Volume48.51K
Average Volume (3M)806.49K
Market Cap
$6.82B
Enterprise Value$6.40B
Total Cash (Recent Filing)$848.28M
Total Debt (Recent Filing)$82.25M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Apr 30, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding81,642,395
10 Day Avg. Volume953,544
30 Day Avg. Volume806,486
Financial Highlights & Ratios
PEG Ratio-0.89
Price to Book (P/B)4.16
Price to Sales (P/S)167.51
P/FCF Ratio-28.02
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue163.38
Enterprise Value/Gross Profit163.38
Enterprise Value/Ebitda-21.18
Forecast
1Y Price Target
$121.72Price Target Upside45.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)-3.6
Revenue Forecast (FY)$41.92M
Bulls Say, Bears Say
Bulls Say
Clinical DataPhase 1b results for KT-621 showed biologic-like reductions in skin lesions and itch with strong STAT6 degradation in tissue, supporting an oral alternative to injectable therapies.
Financial Runway And PartnershipsA substantial cash runway paired with multiple pharmaceutical partnerships supports continued program advancement through key development milestones without immediate financing pressure.
Pipeline ExpansionAdvancement of an IRF5 degrader and a second first-in-human oral candidate with genetic and preclinical support broadens the immune-inflammatory pipeline and increases the chance of multiple clinical wins.
Bears Say
Clinical Translation RiskAchieving meaningful clinical benefit from the IRF5 degrader depends on delivering robust target degradation at safe doses, representing a clear development risk.
Competitive PressureOngoing competitor progress and positive data from rival oral therapies intensify competition in atopic dermatitis and could constrain potential market share.
Valuation And Catalyst VisibilityA high market capitalization based on early-stage, single-arm data combined with a measured near-term catalyst path may prompt valuation pushback and make the stock sensitive to upcoming trial readouts.
Kymera Therapeutics News
KYMR FAQ
What was Kymera Therapeutics’s price range in the past 12 months?
Kymera Therapeutics lowest stock price was $19.45 and its highest was $103.00 in the past 12 months.
What is Kymera Therapeutics’s market cap?
Kymera Therapeutics’s market cap is $6.82B.
When is Kymera Therapeutics’s upcoming earnings report date?
Kymera Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 54 days.
How were Kymera Therapeutics’s earnings last quarter?
Kymera Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.97 earnings per share for the quarter, missing the consensus estimate of -$0.784 by -$0.186.
Is Kymera Therapeutics overvalued?
According to Wall Street analysts Kymera Therapeutics’s price is currently Undervalued.
Does Kymera Therapeutics pay dividends?
Kymera Therapeutics does not currently pay dividends.
What is Kymera Therapeutics’s EPS estimate?
Kymera Therapeutics’s EPS estimate is -0.87.
How many shares outstanding does Kymera Therapeutics have?
Kymera Therapeutics has 81,642,395 shares outstanding.
What happened to Kymera Therapeutics’s price movement after its last earnings report?
Kymera Therapeutics reported an EPS of -$0.97 in its last earnings report, missing expectations of -$0.784. Following the earnings report the stock price went up 4.797%.
Which hedge fund is a major shareholder of Kymera Therapeutics?
Currently, no hedge funds are holding shares in KYMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kymera Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$121.72 (45.79% Upside)
$121.72 (45.79% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $148.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
163.47%
12-Months-Change
Fundamentals
Return on Equity
-25.78%
Trailing 12-Months
Asset Growth
78.20%
Trailing 12-Months
Company Description
Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
KYMR Company Deck
KYMR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical momentum (notably KT-621 and KT-579), significant balance sheet strength (raised ~ $1B; $1.6B year-end cash) and multiple high-value collaborations, all supporting an ambitious development plan. Headwinds include elevated R&D spend (adjusted cash R&D +16% QoQ), limited current revenue, translational/measurement complexity for IRF5, and multi-year timelines to pivotal readouts and potential approvals. Overall, the positives—compelling early clinical data, IND/Phase I starts, partner validation and a multi-year cash runway—outweigh the noted operational and timing risks.View all KYMR earnings summariesKYMR Stock 12 Month Forecast
Average Price Target
$121.72
▲(45.79% Upside)
Technical Analysis
Protagonist Therapeutics
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---